Efficacy study of CyberKnife stereotactic radiosurgery combined with CIK cell immunotherapy for advanced refractory lung cancer

Experimental and Therapeutic Medicine

Volumn 5, Issue 2, 2013, Pages 453-456

  Wang, Yuan Yuan ^a   Wang, Yi Shan ^b   Liu, Tao ^c   Yang, Ke ^a   Yang, Gui Qing ^a   Liu, Han Chen ^b   Wang, Shan Shan ^b   Yang, Jia Lin ^c  

^a BINZHOU MEDICAL UNIVERSITY   (China)

^b Center for Tumor Treatment   (China)

^c Potenbio Biomedical Technical Company   (China)

Author keywords

Clinical efficacy; CyberKnife; Cytokine induced killer; Immunotherapy; Stereotactic radiosurgery

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CD3 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN;

ADVANCED CANCER; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CYBERKNIFE; CYTOKINE INDUCED KILLER CELL; FOLLOW UP; HUMAN; LUNG CANCER; PHENOTYPE; PROTEIN EXPRESSION; RADIATION DOSE; TREATMENT PLANNING;

EID: 84871354890     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2012.818     Document Type: Article

References (26)

1. Ahn SH, Han MS, Yoon JH, etal: Treatment of stage I non-small cell lung cancer with CyberKnife, image-guided robotic stereotactic radiosurgery. Oncol Rep 21: 693-696, 2009.
2. Castelli J, Thariat J, Benezery K, etal: Feasibility and efficacy of cyberknife radiotherapy for lung cancer: early results. Cancer Radiother 12: 793-799, 2008 (In French).
3. Brown WT, Wu X, Wen BC, etal: Early results of CyberKnife image-guided robotic stereotactic radiosurgery for treatment of lung tumors. Comput Aided Surg 12: 253-261, 2007.
4. Brown WT, Wu X, Wen BC, Fowler JF, etal: Lung metastases treated by CyberKnife image-guided robotic stereotactic radiosurgery at 41 months. South Med J 101: 376-382, 2008.
5. Wilcox EE, Daskalov GM, Lincoln H, etal: Comparison of planned dose distributions calculated by Monte Carlo and Ray-Trace algorithms for the treatment of lung tumors with cyberknife: a preliminary study in 33patients. Int J Radiat Oncol Biol Phys 77: 277-284, 2010.
6. Bondiau PY, Doyen J, Mammar H, etal: Reirradiation of spine and lung tumor with CyberKnife. Cancer Radiother 14: 438-441, 2010 (In French).
7. Liu P, Chen L and Huang X: The antitumor effects of CIK cells combined with docetaxel against drug-resistant lung adenocarcinoma cell line SPC-A1/DTX invitro and invivo. Cancer Biother Radiopharm 24: 91-98, 2009.
8. Tome ME, Frye JB, Coyle DL, etal: Lymphoma cells with increased anti-oxidant defenses acquire chemoresistance. Exp Ther Med 3: 845-852, 2012.
9. Goldstraw, P, Crowley J, Chansky K, etal: The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol 2: 706-714, 2007.
10. Gibbs IC and Loo BW Jr: CyberKnife stereotactic ablative radiotherapy for lung tumors. Technol Cancer Res Treat 9: 589-596, 2010.
11. Qiao, X, Tullgren, O, Lax I, etal: The role of radiotherapy in treatment of stage I non-small cell lung cancer. Lung Cancer 41: 1-11, 2003.
12. Collins BT, Vahdat S, Erickson K, etal: Radical cyberknife radiosurgery with tumor tracking: an effective treatment for inoperable small peripheral stage I non-small cell lung cancer. J Hematol Oncol 2: 1, 2009.
13. Sharma SC, Ott JT, Williams JB and Dickow D: Clinical implications of adopting Monte Carlo treatment planning for CyberKnife. J App Clin Med Phys 11: 3142, 2010.
14. Hoogeman M, Prévost JB, Nuyttens J, etal: Clinical accuracy of the respiratory tumor tracking system of the cyberknife: assessment by analysis of log files. Int J Radiat Oncol Biol Phys 74: 297-303, 2009.
15. Timmerman R, Paulus R, Galvin J, etal: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303: 1070-1076, 2010.
16. Whyte RI, Crownover R, Murphy MJ, etal: Stereotactic radiosurgery for lung tumors: preliminary report of a phase I trial. Ann Thorac Surg 75: 1097-1101, 2003.
17. Parkash J: Tumor necrosis factor-α induces transcriptional activation of nuclear factor-κB in insulin-producing β-cells. Exp Ther Med 2: 21-26, 2011.
18. Unger K, Ju A, Oermann E, etal: CyberKnife for hilar lung tumors: report of clinical response and toxicity. J Hematol Oncol 22: 39, 2010.
19. Brown JM, Diehn M and Loo BW Jr: Stereotactic ablative radiotherapy should be combined with a hypoxic cell radiosensitizer. Int J Radiat Oncol Biol Phys 78: 323-327, 2010.
20. Ballen KK, Colvin G, Dey BR, etal: Cellular immune therapy for refractory cancers: novel therapeutic strategies. Exp Hematol 33: 1427-1435, 2005.
21. Hontscha C, Borck Y, Zhou H, etal: Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). JCancer Res Clin Oncol 137: 305-310, 2011.
22. Schmidt-Wolf GD, Negrin RS and Schmidt-Wolf IG: Activated T-cells and cytokine-induced CD3+CD56+ killer cells. Ann Hematol 74: 51-56, 1997.
23. Leemhuis T, Wells S, Scheffold C, etal: A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 11: 181-187, 2005.
24. Schmidt-Wolf IG, Negrin RS, Kiem HP, etal: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med 174: 139-149, 1991.
25. Baker J, Verneris MR, Ito M, etal: Expansion of cytolytic CD8(+) natural killer T-cells with limited capacity for graft-versus-host disease induction due to interferon gamma production. Blood 97: 2923-2931, 2001.
26. Verneris MR, Kornacker M, Mailänder V and Negrin RS: Resistance of exvivo expanded CD3+CD56+ T-cells to Fas-mediated apoptosis. Cancer Immunol Immunother 49: 335-345, 2000.